1887

Abstract

The increasing prevalence of community-associated meticillin-resistant (CA-MRSA) poses a challenge for antimicrobial therapy of skin and soft tissue infections (SSTIs). To determine whether another antimicrobial agent might enhance the activity of moxifloxacin against CA-MRSA, this study analysed its activity alone and in chequerboard combination with doxycycline, rifampicin, clindamycin, trimethoprim, sulfamethoxazole/trimethoprim (SXT) and vancomycin against recent SSTI clinical isolates, and also characterized the isolates for Panton–Valentine leukocidin (PVL), groups, staphylococcal cassette chromosome (SSC) types and -haemolysin production. For comparison, 25 strains of outpatient meticillin-susceptible (MSSA), 24 strains of healthcare-associated (HA)-MRSA and six historical strains of vancomycin-intermediate (VISA) were included. It was found that 21/25 CA-MRSA strains tested were PVL-positive, SSC type 4 and type 1, whilst 4/25 were PVL-negative, SSC type 2 and type 2. Two of the type 2 strains were negative for -haemolysin but all other strains were positive. Moxifloxacin MIC values (μg ml) were 1/8 for CA-MRSA, 4/32 for HA-MRSA and ≤0.03/1 for MSSA and MIC of 2 for VISA. The D-test for inducible clindamycin resistance was positive for 3/27 CA-MRSA, 5/14 HA-MRSA and none of the MSSA isolates. In chequerboard studies, fractional inhibitory concentration indices (FICIs) showed that most interactions were additive or indifferent (FICI value >0.5 to ≤2) as follows: rifampicin 43/52 strains, clindamycin 44/44, SXT 44/47, trimethoprim 41/42 and vancomycin 37/43. The FICI values for doxycycline were 3–6 for 32/34 strains, indicating antagonism, suggesting that it should not be used in combination with moxifloxacin.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47580-0
2008-04-01
2020-07-11
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/4/452.html?itemId=/content/journal/jmm/10.1099/jmm.0.47580-0&mimeType=html&fmt=ahah

References

  1. Buck J. M., Como-Sabetti K., Harriman K. H., Danila R. N., Boxrud D. J., Glennen A., Lynfield R. 2005; Community-associated methicillin-resistant Staphylococcus aureus , Minnesota, 2000–2003. Emerg Infect Dis 11:1532–1538 [CrossRef]
    [Google Scholar]
  2. CLSI 2006 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically ; approved standard, 7th edn. Document M7-A7 Wayne, PA: Clinical and Laboratory Standards Institute;
    [Google Scholar]
  3. Diep B. A., Carleton H. A., Chang R. F., Sensabaugh G. F., Perdeau-Remmington F. 2006; Roles of 34 virulence genes in the evolution of hospital- and community-associated strains of methicillin-resistant Staphylococcus aureus . J Infect Dis 193:1495–1503 [CrossRef]
    [Google Scholar]
  4. Jarraud S., Mougel C., Thiolouse J., Lina G., Meugnier H., Forey F., Nesme X., Etienne J., Vandenesch F. 2002; Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles) and human disease. Infect Immun 70:631–641 [CrossRef]
    [Google Scholar]
  5. Krogstad D. J., Moellering R. C. Jr 1986; Antimicrobial combinations. In Antibiotics in Laboratory Medicine , 2nd edn. Edited by Lorian V. Baltimore, MD: Williams and Wilkins;
    [Google Scholar]
  6. Lina G., Piémont Y., Godail-Gamot F., Bes M., Peter M. O., Gauduchon V., Vandenesch F., Etienne J. 1999; Involvement of Panton–Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 29:1128–1132 [CrossRef]
    [Google Scholar]
  7. Metzler K., Hansen G. M., Hedlin P., Harding E., Drlica K., Blondeau J. M. 2004; Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus . Int J Antimicrob Agents 24:161–167 [CrossRef]
    [Google Scholar]
  8. Moran G. J., Krishnadasan A., Horowitz R. J., Fosheim G. E., McDougal L. K., Carey R. B., Talan D. A. 2006; Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666–674 [CrossRef]
    [Google Scholar]
  9. Noguchi N., Okihara T., Namaki Y., Kumaki Y., Yamanake Y., Koyama M., Wakasugi K., Sasatsu M. 2005; Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. Int J Antimicrob Agents 25:374–379 [CrossRef]
    [Google Scholar]
  10. Sakoulas G., Eliopoulos G. M., Moellering R. C. Jr, Novick R. P., Venkataraman L., Wennerstein C., DeGirolami P. C., Schwaber M. J., Gold H. S. 2003; Staphylococcus aureus accessory gene regulator ( agr ) group II: is there a relationship to the development of intermediate-level glycopeptide resistance ? . J Infect Dis 187:929–938 [CrossRef]
    [Google Scholar]
  11. Sakoulas G., Eliopoulos G. M., Fowler V. G., Moellering R. C. Jr, Novick R. P., Lucindo N., Yeaman M. R., Bayer A. S. 2005; Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator ( agr ) function. Antimicrob Agents Chemother 49:2687–2692 [CrossRef]
    [Google Scholar]
  12. Schrenzel J., Harbarth S., Schockmel G., Genné D., Bregenzer T., Flueckiger U., Petignat C., Jacobs F., Francioli P. other authors 2004; A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacin or vancomycin for the treatment of staphylococcal infections. Clin Infect Dis 39:1285–1292 [CrossRef]
    [Google Scholar]
  13. Stevens D. L., Bisno A. L., Chambers H. F., Everett E. D., Dellinger P., Goldstein E. J. C., Gorbach S. L., Hirschmann J. V., Kaplan E. L. other authors 2005; Skin and soft tissue infections: diagnosis and management guidelines. Clin Infect Dis 41:1373–1406 [CrossRef]
    [Google Scholar]
  14. Vandenesch F., Nami T., Enright M. C., Lina G., Nimmo G. R., Heffernan H., Liassine N., Bes M., Greenland T. other authors 2003; Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton–Valentine leucocidin genes: worldwide emergence. Emerg Infect Dis 9:978–984 [CrossRef]
    [Google Scholar]
  15. Zhang K., McClure J. A., Elsayed S., Louie T., Conly J. M. 2005; Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome SSC mec types I to V in methicillin-resistant Staphylococcus aureus . J Clin Microbiol 43:5026–5033 [CrossRef]
    [Google Scholar]
  16. Zimmerli W., Widmer A. F., Blatter M., Frei R., Ochsner P. E. 1998; Role of rifampicin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. JAMA 279:1537–1541 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.47580-0
Loading
/content/journal/jmm/10.1099/jmm.0.47580-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error